Key result
Percutaneous balloon aortic valvuloplasty remains relevant in the TAVI era for symptom palliation, as a bridge to definitive therapy, and to assess therapeutic response in borderline patients.
This narrative review summarizes the evolving role, indications, techniques, and outcomes of percutaneous balloon aortic valvuloplasty in the TAVI era.
BAV may aid therapeutic response assessment in select AS patients; leaves open need for prospective trials to refine indications.
The role of percutaneous balloon aortic valvuloplasty (BAV) in the management of severe symptomatic aortic stenosis has come under the spotlight following the development of the transcatheter aortic valve implantation (TAVI) technique. Previous indications for BAV were limited to symptom palliation and as a bridge to definitive therapy for patients undergoing conventional surgical aortic valve replacement (AVR). In the TAVI era, BAV may also be undertaken to assess the 'therapeutic response' of a reduction in aortic gradient in borderline patients often with multiple comorbidities, to assess symptomatic improvement prior to consideration of definitive TAVI intervention. This narrative review aims to update the reader on the current indications and practical techniques involved in undertaking a BAV procedure. In addition, a summary of the haemodynamic and clinical outcomes, as well as the frequently encountered procedural complications is presented for BAV procedures conducted during both the pre-TAVI and post-TAVI era.
No takes yet. Share an insight, caveat, or question.
Keeble et al. (2016) conducted a review in Severe symptomatic aortic stenosis. Percutaneous balloon aortic valvuloplasty (BAV) was evaluated. Percutaneous balloon aortic valvuloplasty remains relevant in the TAVI era for symptom palliation, as a bridge to definitive therapy, and to assess therapeutic response in borderline patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: